Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

st

ViroPharma is hosting a live teleconference and webcast with senior management to discuss the financial announcement, guidance, and other business results on February 24, 2009 at 9:00 a.m. Eastern Time. To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.

Alternatively, the live webcast of the conference call can be accessed via ViroPharma's website at http://www.viropharma.com. Windows Media or Real Player will be needed to access the webcast. An audio archive will be available at the same address until March 10, 2009.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, w
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 2015  Naldemedine, an investigational peripherally acting mu-opioid ... Co., Ltd., met its primary and secondary endpoints ... the treatment of opioid-induced constipation (OIC) in adult ... Study results showed that naldemedine (0.2 mg tablet ... of spontaneous bowel movement (SBM) compared with placebo ...
(Date:3/30/2015)... and MADISON, Wis. , ... Shigehiro Nakajima ,) (TSE: 4901) ("Fujifilm") and Cellular Dynamics ... ICEL ) ("CDI"), a leading developer and manufacturer ... precise specifications, today announced that the two companies have ... CDI via an all-cash tender offer to be followed ...
(Date:3/29/2015)... IRVING, Texas , March 29, 2015 ... presentation of study data in small cell ... profiling using Caris Molecular Intelligence®, the company,s ... of certain gene mutations which may explain ... Researchers found that identification of certain biomarkers ...
(Date:3/29/2015)... 2015 As a symbol of its ... our pharmaceutical manufacturing clients, Whitehouse Laboratories is excited to ... Berkenstock Race Team for the 2015 race season. Success ... but a strong sense of precision and attention to ... success in the quality control testing laboratory. Sponsorship of ...
Breaking Biology Technology:Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 2Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 4Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 6Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 7Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 8Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2
... ... hire. Cindy Larkin has been hired as Director of Client Services. Cindy Larkin ... , ... November 3, 2009 -- Leading medical device and life sciences software engineering consulting firm ...
... , PLYMOUTH MEETING, Pa., Nov. 2 BioBehavioral Diagnostics ... October 30, 2009 after it was accepted via a ... Poster presentation at the Annual Meeting of the American ... HI, October 27-November 1, 2009. Calvin R. Sumner, M.D., ...
... Microfluidics International Corporation (OTC Bulletin Board: MFLU), today ... September 30, 2009. , (Logo: ... , Earned net income for the third ... interest, taxes, depreciation and amortization (EBITDA) Delivered strong ...
Cached Biology Technology:Medical Device Software Engineering Firm Full Spectrum Software Appoints Cindy Larkin to Director of Client Services 2Objective Measures of ADHD Symptoms Using the Quotient(TM) ADHD System May Reduce Cost of ADHD Drug Trials 2Objective Measures of ADHD Symptoms Using the Quotient(TM) ADHD System May Reduce Cost of ADHD Drug Trials 3Objective Measures of ADHD Symptoms Using the Quotient(TM) ADHD System May Reduce Cost of ADHD Drug Trials 4Microfluidics International Corporation Announces Third Quarter 2009 Financial Results 2Microfluidics International Corporation Announces Third Quarter 2009 Financial Results 3Microfluidics International Corporation Announces Third Quarter 2009 Financial Results 4Microfluidics International Corporation Announces Third Quarter 2009 Financial Results 5Microfluidics International Corporation Announces Third Quarter 2009 Financial Results 6Microfluidics International Corporation Announces Third Quarter 2009 Financial Results 7Microfluidics International Corporation Announces Third Quarter 2009 Financial Results 8Microfluidics International Corporation Announces Third Quarter 2009 Financial Results 9
(Date:3/10/2015)... March 10, 2015   Tute Genomics , pioneer ... selected by next-generation sequencing company PrimBio Research Institute ... and targeted gene panel interpretation. PrimBio, a ... the most current technologies to support the work of ... company offers two types of exome sequencing services: 1) ...
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biometrics Market Forecast and Opportunities, ... The market for biometric authentication systems is projected ... till 2020 The driving forces for ... needs, government projects and constant development in technology. ...
(Date:3/2/2015)... 2, 2015  Businesses have a new option ... Tharon Rankins Enterprises has announced the launch of ... way for businesses to protect their customers, personal ... Beconux is a biometric transaction processing ... similarly to an ATM machine, the new system ...
Breaking Biology News(10 mins):PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Personal Data Protection Company Launches New Product 2
... drug made to enhance memory appears to trigger a natural ... even after the drug itself has left the body, according ... Gary Lynch, along with Associate Researcher Julie Lauterborn, were among ... a class of drugs known as ampakines. Ampakines were developed ...
... benign compound contained in a widely used group of ... existing pesticides in the environment, according to a new ... Berkeley. , While the increase in toxicity was relatively ... unexpected, the researchers said. , The study's results, reported ...
... so overjoyed are they at hearing her words. What does ... your passion for spicy cuisine. Drink red wine. Enjoy coffee ... and, what the heck, eat a grapefruit, too. Gerson says ... the notion that eating these foods will make heartburn worse ...
Cached Biology News:Drug triggers body's mechanism to reverse aging effect on memory process 2Mosquito spray increases toxicity of pyrethroids in creek, study finds 2Mosquito spray increases toxicity of pyrethroids in creek, study finds 3Mosquito spray increases toxicity of pyrethroids in creek, study finds 4Chocolate, wine, spicy foods may be OK for heartburn, Stanford study finds 2Chocolate, wine, spicy foods may be OK for heartburn, Stanford study finds 3Chocolate, wine, spicy foods may be OK for heartburn, Stanford study finds 4
RAT ANTI MOUSE TCR V BETA 7:RPE Immunogen: T-cell lymphoma TK1...
... Rhesus Serum • Rhesus serum is ... and 5-7 years of age. Available ... Heparin (Na) N-06: K2EDTA ... (Na) N-03: Alsevers N-05: ...
Porcine Serum US Origin 6 Months or Older...
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
Biology Products: